BiotechTubeBiotechTube
Home/Nippon Shinyaku/Yoshihisa Nakagawa
YN

Yoshihisa Nakagawa

Director and Managing Executive Officer

Nippon Shinyaku

Therapeutic Areas

Rare DiseasesNeuromuscular DisordersHematologyMetabolic DisordersOncology

Nippon Shinyaku Pipeline

DrugIndicationPhase
Viltepso (viltolarsen)Duchenne Muscular Dystrophy (exon 53 amenable)Approved
NS-089/NCNP-02Duchenne Muscular Dystrophy (exon 44 amenable)Phase 3
NS-080/NCNP-01Duchenne Muscular Dystrophy (exon 45 amenable)Phase 1/2
Fostamatinib (TAK-632/R788)Immune Thrombocytopenia (ITP)Approved
Miglustat (Brazaves)Niemann-Pick disease type CApproved
NS-0100Undisclosed OncologyPreclinical
NS-0200Undisclosed Rare DiseasePreclinical

Leadership Team at Nippon Shinyaku

SH
Shigeki Hirao
Representative Director and President (CEO)
YK
Yoshihiro Kato
Director and Senior Managing Executive Officer
TS
Takeshi Suda
Director and Senior Managing Executive Officer
KM
Kazuhiko Matsushita
Director and Senior Managing Executive Officer
HK
Hiroshi Kawaguchi
Director and Managing Executive Officer
MK
Masayuki Kondo
Director
YS
Yoshihiko Sano
Director
MS
Masahiko Shibayama
Director
YK
Yoshiko Kita
Director
YY
Yoshihiro Yoneda
Director
View full Nippon Shinyaku profile